Azenta

Azenta's 15min chart shows KDJ Death Cross, Bearish Marubozu signal.

Jefferies Lowers Azenta Price Target to $40, Maintains Buy Rating

Azenta (AZTA) Maintains "Buy" Rating with $44 Price Target from Needham

Azenta Inc Q1 2026 Earnings Call: Strategic Focus, Financial Strength Amid Challenges

Azenta Expects 3-5% Organic Revenue Growth and 300bps Margin Expansion by 2026 Amid Uncertainty

Catalyst<ul> <li>Positive fund flows across all order sizes indicate growing institutional interest in AZTA.</li> <li>Analysts overwhelmingly rate AZTA as Buy or Strong Buy, reflecting strong institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show AZTA in a weak state with bearish signals dominating, increasing the risk of further decline.</li> <li>The company's cash reserves relative to market value are a concern, signaling potential liquidity or valuation challenges.</li></ul>

Key Factors

Azenta (AZTA) reported Q1 2026 earnings on Feb 4, 2026, with results that missed revenue and earnings estimates but maintained full-year guidance. Azenta Inc (AZTA) announced a $250 million share repurchase authorization and $571 million in cash for strategic capital deployment amid operational improvements and margin expansion efforts. Azenta (AZTA) agreed to sell its B Medical Systems business for $63 million, with the transaction expected to close by March 31, 2026, to focus on core capabilities. Jefferies lowered Azenta’s (AZTA) price target to $40 from $42 while maintaining a "Buy" rating, citing updated expectations for the stock. Needham reiterates a "Buy" rating for Azenta (AZTA) and raised its price target to $44 from $40, expressing confidence in the company’s potential growth.

AZTA News